TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.
Brief Summary: This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikayce™ versus placebo and daily dosing of 70 mg and 140 mg of Arikayce™ versus placebo in patients who have Cystic fibrosis (CF) and chronic infection due to pseudomonas aeruginosa.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 560 mg | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for 560 mg | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 70 mg | Arm Label: D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 140 mg | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for 70 mg / 140 mg | Intervention Type: DRUG; Name: Arikayce™ 560 mg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo for 560 mg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Arikayce™ 70 mg; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Arikayce™ 140 mg; Assigned to Arm(s): D | Intervention Type: DRUG; Name: Placebo for 70 mg / 140 mg; Assigned to Arm(s): E
D: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.
Brief Summary: This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikayce™ versus placebo and daily dosing of 70 mg and 140 mg of Arikayce™ versus placebo in patients who have Cystic fibrosis (CF) and chronic infection due to pseudomonas aeruginosa.


Options:
A: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS
B: Arm Label: Aeroquin 240 mg; Type: EXPERIMENTAL; Interventions: Drug: Aeroquin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aeroquin; Assigned to Arm(s): Aeroquin 240 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 560 mg | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for 560 mg | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 70 mg | Arm Label: D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 140 mg | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for 70 mg / 140 mg | Intervention Type: DRUG; Name: Arikayce™ 560 mg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo for 560 mg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Arikayce™ 70 mg; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Arikayce™ 140 mg; Assigned to Arm(s): D | Intervention Type: DRUG; Name: Placebo for 70 mg / 140 mg; Assigned to Arm(s): E

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.
Brief Summary: This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikayce™ versus placebo and daily dosing of 70 mg and 140 mg of Arikayce™ versus placebo in patients who have Cystic fibrosis (CF) and chronic infection due to pseudomonas aeruginosa.


Options:
A: Intervention Type: DRUG; Name: tobramycin; Assigned to Arm(s): N/A
B: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
C: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 560 mg | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for 560 mg | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 70 mg | Arm Label: D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 140 mg | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for 70 mg / 140 mg | Intervention Type: DRUG; Name: Arikayce™ 560 mg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo for 560 mg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Arikayce™ 70 mg; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Arikayce™ 140 mg; Assigned to Arm(s): D | Intervention Type: DRUG; Name: Placebo for 70 mg / 140 mg; Assigned to Arm(s): E

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.
Brief Summary: This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikayce™ versus placebo and daily dosing of 70 mg and 140 mg of Arikayce™ versus placebo in patients who have Cystic fibrosis (CF) and chronic infection due to pseudomonas aeruginosa.


Options:
A: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
B: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)
C: Arm Label: Bramitob; Type: EXPERIMENTAL; Interventions: Drug: tobramycin / Bramitob | Arm Label: TOBI; Type: ACTIVE_COMPARATOR; Interventions: Drug: tobramycin / TOBI | Intervention Type: DRUG; Name: tobramycin / Bramitob; Assigned to Arm(s): Bramitob | Intervention Type: DRUG; Name: tobramycin / TOBI; Assigned to Arm(s): TOBI
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 560 mg | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for 560 mg | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 70 mg | Arm Label: D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arikayce™ 140 mg | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for 70 mg / 140 mg | Intervention Type: DRUG; Name: Arikayce™ 560 mg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo for 560 mg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Arikayce™ 70 mg; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Arikayce™ 140 mg; Assigned to Arm(s): D | Intervention Type: DRUG; Name: Placebo for 70 mg / 140 mg; Assigned to Arm(s): E

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
Brief Summary: The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.


Options:
A: Arm Label: Subcutaneous (SC) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Subcutaneous (SC) Abatacept | Arm Label: Intravenous (IV) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) Abatacept | Intervention Type: DRUG; Name: Subcutaneous (SC) Abatacept; Assigned to Arm(s): Subcutaneous (SC) Abatacept | Intervention Type: DRUG; Name: Intravenous (IV) Abatacept; Assigned to Arm(s): Intravenous (IV) Abatacept
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
C: Arm Label: Tocilizumab 8 mg/kg + DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Permitted DMARDs | Arm Label: Placebo + DMARDs; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Permitted DMARDs | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg + DMARDs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + DMARDs | Intervention Type: DRUG; Name: Permitted DMARDs; Assigned to Arm(s): Placebo + DMARDs, Tocilizumab 8 mg/kg + DMARDs
D: Arm Label: CP-690,550 + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 + methotrexate | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Methotrexate | Intervention Type: DRUG; Name: CP-690,550 + methotrexate; Assigned to Arm(s): CP-690,550 + methotrexate | Intervention Type: DRUG; Name: Placebo + Methotrexate; Assigned to Arm(s): Placebo + methotrexate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
Brief Summary: The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.


Options:
A: Arm Label: Subcutaneous (SC) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Subcutaneous (SC) Abatacept | Arm Label: Intravenous (IV) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) Abatacept | Intervention Type: DRUG; Name: Subcutaneous (SC) Abatacept; Assigned to Arm(s): Subcutaneous (SC) Abatacept | Intervention Type: DRUG; Name: Intravenous (IV) Abatacept; Assigned to Arm(s): Intravenous (IV) Abatacept
B: Arm Label: Phase 1 Etanercept + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Phase 1: Etanercept, Drug: Phase 1: Methotrexate, Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX | Arm Label: Phase 1 Conventional DMARD (SSZ or HCQ) + MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phase 1: Methotrexate, Drug: Phase 1: Conventiaonal DMARD | Intervention Type: BIOLOGICAL; Name: Phase 1: Etanercept; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 2: Optional ETN, SSZ, HCQ, MTX; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX | Intervention Type: DRUG; Name: Phase 1: Conventiaonal DMARD; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX
C: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)
D: Arm Label: ETN Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN Alone | Arm Label: ETN+MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN+MTX | Intervention Type: DRUG; Name: ETN Alone; Assigned to Arm(s): ETN Alone | Intervention Type: DRUG; Name: ETN+MTX; Assigned to Arm(s): ETN+MTX

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
Brief Summary: The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.


Options:
A: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Biological: Golimumab 50 mg | Arm Label: Group 2: Golimumab 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg | Arm Label: Group 3: Golimumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1: Placebo, Group 2: Golimumab 50 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Group 3: Golimumab 100 mg
B: Arm Label: Subcutaneous (SC) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Subcutaneous (SC) Abatacept | Arm Label: Intravenous (IV) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) Abatacept | Intervention Type: DRUG; Name: Subcutaneous (SC) Abatacept; Assigned to Arm(s): Subcutaneous (SC) Abatacept | Intervention Type: DRUG; Name: Intravenous (IV) Abatacept; Assigned to Arm(s): Intravenous (IV) Abatacept
C: Arm Label: Placebo Plus Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Other: Placebo | Arm Label: Rituximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: MabThera/Rituxan, Drug: Methotrexate | Intervention Type: DRUG; Name: MabThera/Rituxan; Assigned to Arm(s): Rituximab plus Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo Plus Methotrexate, Rituximab plus Methotrexate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Plus Methotrexate
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Response
Brief Summary: The study objectives are to investigate the toxicity and the BUMEL response rate; in patients who reach the CR after autotransplantation, investigate if negativization of IF, influences in disease evolution; in patients in PR after autotransplantation, analyze if the second intensive procedure is capable of increasing the response rate and increasing the survival so that patients who reached the CR with the first transplantation; Patients with MM primarily resistant to the chemotherapy, investigate the efficacy of a double transplantation; patients submitted to double transplantation, control the efficacy of the second transplantation in front of allogenic transplantation.


Options:
A: Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: autologous PBSC transplant; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Alternating chemotherapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Autologous Transplantation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Maintenance; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Second transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: ALOGENIC MINI TRASPLANTATION; Assigned to Arm(s): N/A
D: Arm Label: VTD; Type: EXPERIMENTAL; Interventions: Drug: Velcade, Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Arm Label: TD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): VTD | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): TD, VTD | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Peripheral Blood Stem Cell (PBSC) collection; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: First Autologous Transplantation; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Second Autologous Transplantation; Assigned to Arm(s): TD, VTD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children
Brief Summary: Much has been learned in recent years about the mechanisms by which breastfeeding improves child health and survival. However, there has been little progress in using these insights to improve pediatric care. Factors that are important for protecting the breast fed infant might be expected to decrease the adverse effects of weaning on diarrhea, growth, and development. The proposed study is meant to begin addressing this important gap by a clinical trial of lactoferrin supplementation in previously weaned children. Lactoferrin,an iron-binding protein with multiple physiological functions (anti-microbial, anti-inflammatory, and immunomodulatory), is one of the most important proteins present in mammalian milk. Our hypothesis is that lactoferrin (given as a daily supplement in amounts similar to those consumed if the child were still breastfed) will improve health by mimicking its protective roles in milk. The significance of these studies is that they will prove feasibility of improving child health after the end of breastfeeding by continuing ingestion of a major protective milk protein. Diarrhea and malnutrition after weaning is a global problem that may be amenable to this approach.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Talactoferrin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Talactoferrin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Lactoferrin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: lactoferrin | Arm Label: maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: lactoferrin; Assigned to Arm(s): Lactoferrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): maltodextrin
C: Arm Label: Bovine Lactoferrin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Bovine Lactoferrin | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bovine Lactoferrin; Assigned to Arm(s): Bovine Lactoferrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: bovine lactoferrin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo [maltodextrin] | Intervention Type: DIETARY_SUPPLEMENT; Name: bovine lactoferrin; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo [maltodextrin]; Assigned to Arm(s): B

Answer: D